Table 3 Factors associated with CR of severe asthma

Age (mean, SD)

55

11.2

50.1

13

0.12

Sex (n, %)

 Female

66

69.47

14

66.67

0.81

 Male

29

30.53

7

33.33

BMI (mean, SD)

31.27

5.29

31.21

5.46

0.96

Smoking (n, %)

 Ex-smoker

8

8.42

3

14.29

0.15

 Non-smoker

79

83.16

18

85.71

 Smoker

8

8.42

0

0

Disease onset (n, %)

 Adult-onset

73

76.84

14

66.67

0.33

 Childhood-onset

22

23.16

7

33.33

Comorbidity (n, %)

77

81.05

17

80.95

0.99

 AR (n, %)

46

48.42

14

66.67

0.13

 NP (n, %)

5

5.26

3

14.29

0.14

 Eczema (n, %)

19

20

1

4.76

0.09

 DM (n, %)

15

15.79

1

4.76

0.18

 HTN (n, %)

8

8.42

3

14.29

0.41

Investigations

 FeNO (median, IQR)

22

(14–31)

21

(17–26)

0.95

 Total IgE (median, IQR)

261

(69–691)

98

(24–563)

0.18

 BEC (median, IQR)

235

(113–610)

410

(130–755)

0.27

Phenotypes (n, %)

 Allergic

25

26.32

5

23.81

0.81

 Allergic eosinophilic

70

73.68

16

76.19

IL-4gene polymorphism (n, %)

 CC

45

47.37

15

71.43

0.04^*

 CT

42

44.21

5

23.81

0.07

 TT

8

8.42

1

4.76

0.57

 CC + CT (dominant)

87

91.58

20

95.24

0.57

 CT + TT (Recessive)

50

52.63

6

28.57

0.04^*

TNF-αgene polymorphism (n, %)

 GG

51

53.68

16

76.19

0.05^*

 GA

39

41.05

4

19.05

0.04^*

 AA

5

5.26

1

4.76

0.92

 GG + GA (dominant)

90

94.74

20

95.24

0.92

 GA + AA (recessive)

44

46.32

5

23.81

0.05^*

Biologic Treatment (n, %)

 Dupilumab

32

33.68

14

66.67

0.005^*

 Omalizumab

57

60

9

42.86

0.15